VolitionRx Slides 34%: Why Investors Fear a Biotech Slide
VolitionRx’s stock drops 34% as investors question its epigenetic test viability, liquidity, and regulatory path—why the biotech’s value remains bleak.
3 minutes to read
VOLITIONRX LTD
Volitionrx (VNRX) Flat at $0.17: Market Risks Outweigh Epigenetic Potential
Volitionrx (VNRX) remains stagnant at $0.17, far below its 200‑day SMA, amid a 34.6% monthly decline—investors weigh epigenetic cancer tech against sharp market risk.
2 minutes to read